Among recipients of high-dose chemotherapy for the management of hematologic malignancy, neutropenia is highly correlated with risk of infectious complications [7]. In this patient group,
G-
CSF reduces the duration of neutropenia [8–10].
G-
CSF has been demonstrated to be useful in reducing risk of infection in some [9, 11], but not all, studies [8, 10, 12]. This specific beneficial effect diminishes with increasing age. Overall mortality is generally not altered by the use of G-CSF.